Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
2.300
+0.080 (3.60%)
At close: Sep 2, 2025, 4:00 PM
2.280
-0.020 (-0.87%)
After-hours: Sep 2, 2025, 4:10 PM EDT

Immix Biopharma Statistics

Total Valuation

Immix Biopharma has a market cap or net worth of $66.32 million. The enterprise value is $54.28 million.

Market Cap66.32M
Enterprise Value 54.28M

Important Dates

The last earnings date was Friday, August 8, 2025, after market close.

Earnings Date Aug 8, 2025
Ex-Dividend Date n/a

Share Statistics

Immix Biopharma has 28.83 million shares outstanding. The number of shares has increased by 25.52% in one year.

Current Share Class 28.83M
Shares Outstanding 28.83M
Shares Change (YoY) +25.52%
Shares Change (QoQ) +0.95%
Owned by Insiders (%) 20.37%
Owned by Institutions (%) 12.65%
Float 19.04M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 13.55
P/TBV Ratio 13.94
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.22.

Current Ratio 1.23
Quick Ratio 1.16
Debt / Equity 0.22
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -162.04% and return on invested capital (ROIC) is -96.90%.

Return on Equity (ROE) -162.04%
Return on Assets (ROA) -66.85%
Return on Invested Capital (ROIC) -96.90%
Return on Capital Employed (ROCE) -422.78%
Revenue Per Employee n/a
Profits Per Employee -$1.10M
Employee Count21
Asset Turnover n/a
Inventory Turnover n/a

Taxes

In the past 12 months, Immix Biopharma has paid $40,665 in taxes.

Income Tax 40,665
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +7.48% in the last 52 weeks. The beta is 0.25, so Immix Biopharma's price volatility has been lower than the market average.

Beta (5Y) 0.25
52-Week Price Change +7.48%
50-Day Moving Average 2.49
200-Day Moving Average 2.09
Relative Strength Index (RSI) 47.87
Average Volume (20 Days) 261,560

Short Selling Information

The latest short interest is 122,600, so 0.43% of the outstanding shares have been sold short.

Short Interest 122,600
Short Previous Month 195,159
Short % of Shares Out 0.43%
Short % of Float 0.64%
Short Ratio (days to cover) 0.47

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -23.78M
Pretax Income -18.18M
Net Income -23.13M
EBITDA -23.66M
EBIT -23.78M
Earnings Per Share (EPS) -$0.78
Full Income Statement

Balance Sheet

The company has $11.64 million in cash and $1.04 million in debt, giving a net cash position of $10.60 million or $0.37 per share.

Cash & Cash Equivalents 11.64M
Total Debt 1.04M
Net Cash 10.60M
Net Cash Per Share $0.37
Equity (Book Value) 4.65M
Book Value Per Share 0.16
Working Capital 2.32M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$12.51 million and capital expenditures -$974,036, giving a free cash flow of -$13.48 million.

Operating Cash Flow -12.51M
Capital Expenditures -974,036
Free Cash Flow -13.48M
FCF Per Share -$0.47
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Immix Biopharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -25.52%
Shareholder Yield -25.52%
Earnings Yield -35.65%
FCF Yield -20.78%

Analyst Forecast

The average price target for Immix Biopharma is $7.00, which is 204.35% higher than the current price. The consensus rating is "Strong Buy".

Price Target $7.00
Price Target Difference 204.35%
Analyst Consensus Strong Buy
Analyst Count 1
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 1